

## FY25 Quarterly Evaluation and Performance Measures Reporting Form

Grantee Name: _____	
Grant Number: 03420-	
Reporting Period (select one):	<input type="checkbox"/> Period 1 Report (September 1, 2024 – November 30, 2024) Due 12/30/24 <input type="checkbox"/> Period 2 Report (December 1, 2024 – February 28, 2025) Due 3/30/25 <input type="checkbox"/> Period 3 Report (March 1, 2025 – May 31, 2025) Due 6/30/25 <input type="checkbox"/> Period 4 Report (June 1, 2025 – August 31, 2025) Due 9/30/25 <input type="checkbox"/> Other _____

### Instructions:

Complete the following sections regarding your organization's Overdose Data to Action subgrant with the Vermont Department of Health's Division of Substance Use Programs. This report is due according to the terms of your grant and must be submitted via Alchemer at this link:

<https://survey.alchemer.com/s3/8039388/FY25-OD2A-Reporting>

### Reporting Period Successes

1. Please share brief, key successes of the program/project during this reporting period:

### Reporting Period Challenges

2. Please share brief, key challenges of the program/project during this reporting period:

## Reporting Period Progress Narrative

- 3. Please provide a detailed narrative of the progress the program/project has made during the reporting period.**

*Note: Reporting on the Quantity and/or Quality Indicators included in 'Table 1 - Performance Indicators' and the requirements included in 'Section 3: Required Services and Activities' and of Attachment A of your grant is required:*

- 4. Please provide a summative narrative of the progress your program/project has made during the entire project period if not included in above successes, challenges, and narrative sections(\*for final report only).**

*Note: Reporting on the Quantity and/or Quality Indicators included in 'Table 1 - Performance Indicators' and the requirements included in 'Section 3: Required Services and Activities' and of Attachment A of your grant is required*

## Health Equity: Number of health equity focused overdose prevention activities implemented with OD2A funding:

Health equity focused overdose prevention activities address health equity by serving (directly or indirectly) populations who have been disproportionately affected by the overdose epidemic, populations underserved by overdose prevention programs, or populations less well served by the healthcare system in general.

**These activities can include:**

- Examining and enhancing methods to collect health equity data
- Training staff or professionals on health equity related topics
- Amplifying voices and experiences of populations disproportionately affected by overdose or populations that have been underserved by overdose prevention services and programs.
- Implementing and/or tailoring interventions and programs to better address the needs of populations disproportionately affected by overdose and underserved by overdose prevention programs.

**Populations of focus in VT under OD2A include:**

- people who have recently experienced an overdose
- people recently released from an institution
- people experiencing homelessness/unstable housing
- people aged 25-44, living in rural areas
- people in high-risk occupations such as construction, service (e.g. restaurants and housekeeping) and healthcare
- Pregnant people / new families

**Reporting your number of health equity activities** (if you have no activities to report this period enter 0)-

1. Number of Health Equity activities: \_\_\_\_\_

Of the above activities, list the # that occurred in a Clinical setting \_\_\_\_\_

Of the above activities, list the # that occurred in a Harm reduction setting \_\_\_\_\_

Of the above activities, list the # that occurred in a public safety setting \_\_\_\_\_

Of the above activities, list the # that occurred in an "other" setting \_\_\_\_\_

**Describe these activities:** (if you have no comments for this reporting period please enter "NA")

2. Please describe the health equity focused overdose prevention activities implemented or conducted

3. Please describe the intended audience or who participated

## Health Equity: Number of health equity focused overdose prevention activities implemented with OD2A funding: (Continued)

4. How were these activities tailored to suit a population of focus listed above?

5. Describe any issues, concerns or additional information that would help us better understand the answers you have entered in this section(optional)

## Number of clinicians who received training on implementing the “2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain”

Please report the number of clinicians whose scope and practice includes prescribing opioids who were trained on the “2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain” using OD2A funds. These clinicians can include physicians, nurse practitioners or other advanced practice RNs, physician assistants, or oral health providers.

### **Report the number trained:**

1. Total number of clinicians trained \_\_\_\_\_

### **Describe the training:**

2. Describe the trainings including the title, number offered, length, who conducted them, and where the training occurred.

3. **Optional.** What populations are served by the clinicians who were trained?

4. What are barriers to effectively training clinicians on the “2022 CDC Clinical Practice Guideline”?

5. What are facilitators to effectively training clinicians on the “2022 CDC Clinical Practice Guideline”?

6. Describe any issues, concerns or additional information that would help us better understand the answers you have entered in this section(optional)

## Number of health/clinical settings implementing or improving protocols and/or policies for evidence-based SUD treatment or referrals

### **Report the number of health settings that have improved or implemented policies or protocols for SUD (substance use disorder) treatment or referrals to that treatment:**

1. Please report the number of unique clinical settings who have implemented or improved protocols/policies for treatment of SUD as a result of your work under OD2A. \_\_\_\_\_

2. Please report the number of unique clinical settings who have implemented or improved protocols/policies for **referral** to treatment for SUD as a result of your work under OD2A. \_\_\_\_\_

3. Please report the total number of unique health settings who have implemented or improved protocols for **or** referral for SUD treatment as a result of your work under OD2A. *(please note this number may not be a simple addition of the numbers above if a single unique clinical setting has implement or improved a protocol for SUD treatment in addition to implementing or improving a policy for referral to SUD treatment)* \_\_\_\_\_

### **Describe the Clinical setting and protocol/policy changes:**

4. Describe how access to MOUD for healthcare settings has changed since implementing policies or protocols.

5. Describe the partnerships for SUD referral with the health settings included in this indicator. What steps were taken to develop and build the partnerships for SUD referrals?

6. What types of health settings are included in the reported data?

7. Describe any issues, concerns or additional information that would help us better understand the answers you have entered in this section(optional).